Sugi Predict

Sugi Predict / Compounds / SCHEMBL2909170

SCHEMBL2909170

SCHEMBL2909170

O=S(=O)(Cl)Cc1cccc(F)c1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 3/20 0.47
▸ IDO1 P14902 2/20 0.46
▸ AGXT P21549 2/20 0.46
▸ MEN1 O00255 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ MIF P14174 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ DAO P14920 1/20 0.40
▸ GRM4 Q14833 1/20 0.40
▸ SLC6A3 Q01959 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ PARP14 Q460N5 1/20 0.39
▸ TAS2R14 Q9NYV8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5146595 0.85 CYP19A1 (0.40) —
SCHEMBL775777 0.83 TAAR1 (0.50) TAAR1IDO1AGXTMEN1KMT2A
SCHEMBL777783 0.82 TAAR1 (0.48) TAAR1IDO1AGXTMEN1KMT2A
SCHEMBL9421730 0.82 FAAH (0.59) TAAR1IDO1AGXTMEN1KMT2A
SCHEMBL2239914 0.81 TAAR1 (0.53) TAAR1IDO1AGXTMEN1KMT2A
SCHEMBL2376187 0.80 TAAR1 (0.47) TAAR1IDO1AGXTMEN1KMT2A
SCHEMBL3218746 0.80 CA1 (0.57) TAAR1IDO1AGXTMEN1KMT2A
SCHEMBL6653236 0.80 TAAR1 (0.47) TAAR1IDO1AGXTMEN1KMT2A
SCHEMBL776710 0.80 TAAR1 (0.47) TAAR1IDO1AGXTMEN1KMT2A
SCHEMBL9394710 0.79 IDO1 (0.38) IDO1DAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3426246-B1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF NATIONAL HEALTH RES INST (TW) 2024-05-01 — — EP disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 — — US disclosed
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death HEPAREGENIX GMBH (DE) 2024-02-27 — — US disclosed
WO-2023011301-A1 JAK INHIBITOR WITH HIGH ORAL BIOAVAILABILITY 嘉兴特科罗生物科技有限公司 2023-02-09 — — WO disclosed
WO-2021213353-A1 AMIDE OR SULFONAMIDE DERIVATIVE AND USE THEREOF 苏州恩华生物医药科技有限公司 (CN) 2021-10-28 — — WO disclosed
CN-108883099-B Thiazolidinone compounds and use thereof 石全 2021-09-28 — — CN disclosed
US-10544113-B2 Thiazolidinone compounds and use thereof NATIONAL HEALTH RESEARCH INSTITUTE (TW) 2020-01-28 — — US disclosed
EP-3126329-B1 N-HYDROXYMETHANESULFONAMIDE NITROXYL DONORS CARDIOXYL PHARMACEUTICALS INC (US) 2019-05-29 — — EP disclosed
EP-3426246-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF National Health Research Institutes (TW) 2019-01-16 — — EP disclosed
CN-108883099-A THIAZOLIDINONE COMPOUNDS AND USE THEREOF 石全 2018-11-23 — — CN disclosed
CN-101031541-A 4-aminomethyl benzamidine derivatives and their use as factor VIIIa inhibitors HOFFMANN LA ROCHE (CH) 2007-09-05 — — CN disclosed
EP-1791810-A1 4-AMINOMETHYL BENZAMIDINE DERIVATIVES AND THEIR USE AS FACTOR VIIA INHIBITORS F. Hoffmann-Roche AG (CH) 2007-06-06 — — EP disclosed
US-20060116410-A1 4-Aminomethyl benzamidine derivatives HOFFMANN-LA ROCHE INC. 2006-06-01 — — US disclosed
WO-2006027135-A1 4-AMINOMETHYL BENZAMIDINE DERIVATIVES AND THEIR USE AS FACTOR VIIIA INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-16 — — WO disclosed
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors COLLONGES FRANCOIS (FR) 2003-10-30 — — US disclosed
CN-1112356-C Nitromethylthiobenzene derivatives as inhibitors of aldose reductase MERCK PATENT GMBH (DE) 2003-06-25 — — CN disclosed
US-6509499-B1 Nervous system disorders, vision defects, diabetic retinopathy, neuropathic pain and kidney disorder treatment MERCK PATENTGESELLSCHAFT MIT (DE) 2003-01-21 — — US disclosed
EP-0804464-B1 AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS CORVAS INT INC (US) 2002-05-08 — — EP disclosed
CN-1241997-A Nitromethylthiobenzene derivatives as inhibitors of aldose reductase MERCK PATENT GMBH (DE) 2000-01-19 — — CN disclosed
CN-1169730-A Aromatic heterocyclic derivatives as enzyme inhibitors CORVAS INT INC (US) 1998-01-07 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912701-B2 Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death MAPK4, MAPK7, MAPK14 TAAR1 2430/4885IDO1 3441/4885AGXT 407/4885
US-10544113-B2 Thiazolidinone compounds and use thereof OPRL1, OPRD1, OPRK1 TAAR1 115/4885IDO1 1282/4885AGXT 2297/4885
US-20060116410-A1 4-Aminomethyl benzamidine derivatives F7, HABP2, F12 TAAR1 2132/4885IDO1 951/4885AGXT 31/4885
US-20030203966-A1 Nitromethylthiobenzene derivatives as aldose reductase inhihibitors AKR1B1, ALDOA, AKR1C1 TAAR1 2330/4885IDO1 247/4885AGXT 194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.